Concepedia

Author

Hyeryun Kim

Agios Pharmaceuticals (United States)

Also Known As

Hye-Ryun Kim, HyeRyun Kim, Hyeryun Kim, Kim Hye-Ryun

80

Publications

2.8K

Citations

18

H-Index

102

Concepts

All Affiliations

Agios Pharmaceuticals (United States)Yonsei UniversitySungkyunkwan UniversitySamsung Medical CenterAsan Medical Center
HK

About

Hyeryun Kim is an author at Agios Pharmaceuticals (United States) specializing in medicine, health sciences, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

13

13

2.1K

2

Health Sciences

8

8

544

3

Engineering

3

3

71

4

Public Health

1

1

10

5

Social Sciences

1

1

63

Hyeryun Kim

×

26

Publications

2.7K

Citations

18

H-Index

YearCitations

Electrophilic properties of itaconate and derivatives regulate the IκBζ–ATF3 inflammatory axis

Monika Bambousková, Laurent Gorvel, Vicky Lampropoulou,

Nature

2018

695

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers

Janeta Popovici-Müller, René M. Lemieux, Erin Artin,

ACS Medicinal Chemistry Letters

2018

422

Metabolic Profiling Using Stable Isotope Tracing Reveals Distinct Patterns of Glucose Utilization by Physiologically Activated CD8+ T Cells

H. Eric, Mark Verway, Radia Marie Johnson,

Immunity

2019

395

Comparative evaluation of itaconate and its derivatives reveals divergent inflammasome and type I interferon regulation in macrophages

Amanda Swain, Monika Bambousková, Hyeryun Kim,

Nature Metabolism

2020

302

Itaconate confers tolerance to late NLRP3 inflammasome activation

Monika Bambousková, Lucie Potůčková, Tomáš Paulenda,

Cell Reports

2021

216

Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma

Darrell R. Borger, Lipika Goyal, Thomas Yau,

Clinical Cancer Research

2014

132

Isocitrate Dehydrogenase 1 (<i>IDH1</i>) Mutation in Breast Adenocarcinoma Is Associated With Elevated Levels of Serum and Urine 2-Hydroxyglutarate

Amir T. Fathi, Hossein Sadrzadeh, Amy Comander,

The Oncologist

2014

74

CNS response to osimertinib in patients (pts) with T790M-positive advanced NSCLC: Data from a randomized phase III trial (AURA3).

Tony Mok, Myung‐Ju Ahn, Ji‐Youn Han,

Journal of Clinical Oncology

2017

63

A phase II trial of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC).

Min Hee Hong, Hyeryun Kim, Sung Yong Park,

Journal of Clinical Oncology

2019

46

Decreased activity and stability of pyruvate kinase in sickle cell disease: a novel target for mitapivat therapy

Minke A.E. Rab, Jennifer Bos, Brigitte A. van Oirschot,

Blood

2021

42

Page 1